Literature DB >> 9649360

Interactions of griseofulvin with cyclodextrins in solid binary systems.

M D Veiga1, P J Díaz, F Ahsan.   

Abstract

Griseofulvin/cyclodextrin interactions were investigated in aqueous environment and in solid state. Two cyclodextrin derivatives (beta-cyclodextrin and 2-hydroxypropyl beta-cyclodextrin) were used to prepare different physical mixtures and kneaded systems, and the drug/cyclodextrin ratios were 1:1 and 1:2 mol/mol. Scanning electron microscopy (SEM), hot-stage microscopy (HSM), differential scanning calorimetry (DSC), thermogravimetry (TG), and X-ray powder diffractometry were employed to characterize pure substances and their kneaded counterparts and all of the binary systems. The solubility of griseofulvin was increased in accord with the quantity of cyclodextrin added. HSM examination revealed that 2-hydroxypropyl-beta-cyclodextrin was dissolved in the droplets of melted griseofulvin, but did not show any interactions between melted griseofulvin and beta-cyclodextrin particles. The presence of griseofulvin endothermic peak in the DSC curves of all binary systems suggests the absence of any griseofulvin/cylcodextrin inclusion compound in the solid state. In TG, data of weight loss owing to the dehydration of cyclodextrins was similar for both kneaded systems and physical mixtures. X-ray diffraction patterns exhibited the amorphous nature of 2-hydroxypropyl-beta-cyclodextrin and the crystalline nature of griseofulvin and binary systems. Griseofulvin dissolution profiles from all binary systems showed an improvement in drug dissolution, which indicates that an "in situ" drug/cyclodextrin inclusion compound was formed in the aqueous dissolution medium.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649360     DOI: 10.1021/js970233x

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Improving solubility and oral bioavailability of a novel antimalarial prodrug: comparing spray-dried dispersions with self-emulsifying drug delivery systems.

Authors:  Suresh Potharaju; Shravan Kumar Mutyam; Mingtao Liu; Carol Green; Lisa Frueh; Aaron Nilsen; Sovitj Pou; Rolf Winter; Michael K Riscoe; Gita Shankar
Journal:  Pharm Dev Technol       Date:  2020-02-12       Impact factor: 3.133

2.  Solid dispersions of imidazolidinedione by PEG and PVP polymers with potential antischistosomal activities.

Authors:  Francimary L Guedes; Boaz G de Oliveira; Marcelo Z Hernandes; Carlos A De Simone; Francisco J B Veiga; Maria do Carmo A de Lima; Ivan R Pitta; Suely L Galdino; Pedro José Rolim Neto
Journal:  AAPS PharmSciTech       Date:  2011-03-01       Impact factor: 3.246

Review 3.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

4.  A novel solid dosage form of rifampicin and isoniazid with improved functionality.

Authors:  Mukesh C Gohel; Krishnakant G Sarvaiya
Journal:  AAPS PharmSciTech       Date:  2007-08-24       Impact factor: 3.246

5.  Preparation and solid-state characterization of inclusion complexes formed between miconazole and methyl-beta-cyclodextrin.

Authors:  Andreza Ribeiro; Ana Figueiras; Delfim Santos; Francisco Veiga
Journal:  AAPS PharmSciTech       Date:  2008-10-31       Impact factor: 3.246

6.  Antisolvent precipitative immobilization of micro and nanostructured griseofulvin on laboratory cultured diatom frustules for enhanced aqueous dissolution.

Authors:  Megha Thakkar; Mohammad Saiful Islam; Aditya Railkar; Somenath Mitra
Journal:  Colloids Surf B Biointerfaces       Date:  2020-08-07       Impact factor: 5.268

7.  Enhanced Solubility and Anticancer Potential of Mansonone G By β-Cyclodextrin-Based Host-Guest Complexation: A Computational and Experimental Study.

Authors:  Panupong Mahalapbutr; Piyanuch Wonganan; Thanapon Charoenwongpaiboon; Manchumas Prousoontorn; Warinthorn Chavasiri; Thanyada Rungrotmongkol
Journal:  Biomolecules       Date:  2019-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.